The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment

Navneet S. Majhail, Elizabeth A. Murphy, Ellen M. Denzen, Stacy S. Ferguson, Claudio Anasetti, Arthur Bracey, Linda Burns, Richard Champlin, Norman Hubbard, Miriam Markowitz, Richard Maziarz, Erin Medoff, Joyce Neumann, Kim Schmit-Pokorny, Daniel J. Weisdorf, Deborah S. Yolin Raley, Jeffrey Chell, Edward L. Snyder

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor Program® (NMDP) will facilitate 10,000 transplants by 2015, double the current number. To better understand the existing personnel and center infrastructure for HCT in the country and to address system capacity challenges to the future growth of HCT, the NMDP convened a diverse group of stakeholders and thought leaders representing HCT physicians, physician assistants, nurse practitioners, nurses, pharmacists, other healthcare providers, HCT program directors, hospital administrators, payors, and professional organizations. Working groups were formed to identify: capacity issues because of shortages in human resources, structural constraints, and patient access barriers including diversity and healthcare disparity challenges; recommendations to address challenges; and stakeholders to engage. This report details the deliberations and recommendations of a national symposium, " Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment," held in September 2010.

Original languageEnglish (US)
Pages (from-to)172-182
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Health Resources
Cell Transplantation
Bone Marrow
Tissue Donors
Delivery of Health Care
Healthcare Disparities
Hospital Administrators
Physician Assistants
Nurse Practitioners
Hematologic Diseases
Pharmacists
Health Personnel
Nurses
Physicians
Transplants
Growth

Keywords

  • Hematopoietic cell transplantation
  • National Marrow Donor Program
  • System capacity
  • Workforce shortage

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020 : A Health Care Resource and Infrastructure Assessment. / Majhail, Navneet S.; Murphy, Elizabeth A.; Denzen, Ellen M.; Ferguson, Stacy S.; Anasetti, Claudio; Bracey, Arthur; Burns, Linda; Champlin, Richard; Hubbard, Norman; Markowitz, Miriam; Maziarz, Richard; Medoff, Erin; Neumann, Joyce; Schmit-Pokorny, Kim; Weisdorf, Daniel J.; Yolin Raley, Deborah S.; Chell, Jeffrey; Snyder, Edward L.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 2, 02.2012, p. 172-182.

Research output: Contribution to journalArticle

Majhail, NS, Murphy, EA, Denzen, EM, Ferguson, SS, Anasetti, C, Bracey, A, Burns, L, Champlin, R, Hubbard, N, Markowitz, M, Maziarz, R, Medoff, E, Neumann, J, Schmit-Pokorny, K, Weisdorf, DJ, Yolin Raley, DS, Chell, J & Snyder, EL 2012, 'The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment', Biology of Blood and Marrow Transplantation, vol. 18, no. 2, pp. 172-182. https://doi.org/10.1016/j.bbmt.2011.10.004
Majhail, Navneet S. ; Murphy, Elizabeth A. ; Denzen, Ellen M. ; Ferguson, Stacy S. ; Anasetti, Claudio ; Bracey, Arthur ; Burns, Linda ; Champlin, Richard ; Hubbard, Norman ; Markowitz, Miriam ; Maziarz, Richard ; Medoff, Erin ; Neumann, Joyce ; Schmit-Pokorny, Kim ; Weisdorf, Daniel J. ; Yolin Raley, Deborah S. ; Chell, Jeffrey ; Snyder, Edward L. / The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020 : A Health Care Resource and Infrastructure Assessment. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 2. pp. 172-182.
@article{2b6de98bae444d8fb3a2ec128d2e2e5d,
title = "The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment",
abstract = "Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor Program{\circledR} (NMDP) will facilitate 10,000 transplants by 2015, double the current number. To better understand the existing personnel and center infrastructure for HCT in the country and to address system capacity challenges to the future growth of HCT, the NMDP convened a diverse group of stakeholders and thought leaders representing HCT physicians, physician assistants, nurse practitioners, nurses, pharmacists, other healthcare providers, HCT program directors, hospital administrators, payors, and professional organizations. Working groups were formed to identify: capacity issues because of shortages in human resources, structural constraints, and patient access barriers including diversity and healthcare disparity challenges; recommendations to address challenges; and stakeholders to engage. This report details the deliberations and recommendations of a national symposium, {"} Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment,{"} held in September 2010.",
keywords = "Hematopoietic cell transplantation, National Marrow Donor Program, System capacity, Workforce shortage",
author = "Majhail, {Navneet S.} and Murphy, {Elizabeth A.} and Denzen, {Ellen M.} and Ferguson, {Stacy S.} and Claudio Anasetti and Arthur Bracey and Linda Burns and Richard Champlin and Norman Hubbard and Miriam Markowitz and Richard Maziarz and Erin Medoff and Joyce Neumann and Kim Schmit-Pokorny and Weisdorf, {Daniel J.} and {Yolin Raley}, {Deborah S.} and Jeffrey Chell and Snyder, {Edward L.}",
year = "2012",
month = "2",
doi = "10.1016/j.bbmt.2011.10.004",
language = "English (US)",
volume = "18",
pages = "172--182",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020

T2 - A Health Care Resource and Infrastructure Assessment

AU - Majhail, Navneet S.

AU - Murphy, Elizabeth A.

AU - Denzen, Ellen M.

AU - Ferguson, Stacy S.

AU - Anasetti, Claudio

AU - Bracey, Arthur

AU - Burns, Linda

AU - Champlin, Richard

AU - Hubbard, Norman

AU - Markowitz, Miriam

AU - Maziarz, Richard

AU - Medoff, Erin

AU - Neumann, Joyce

AU - Schmit-Pokorny, Kim

AU - Weisdorf, Daniel J.

AU - Yolin Raley, Deborah S.

AU - Chell, Jeffrey

AU - Snyder, Edward L.

PY - 2012/2

Y1 - 2012/2

N2 - Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor Program® (NMDP) will facilitate 10,000 transplants by 2015, double the current number. To better understand the existing personnel and center infrastructure for HCT in the country and to address system capacity challenges to the future growth of HCT, the NMDP convened a diverse group of stakeholders and thought leaders representing HCT physicians, physician assistants, nurse practitioners, nurses, pharmacists, other healthcare providers, HCT program directors, hospital administrators, payors, and professional organizations. Working groups were formed to identify: capacity issues because of shortages in human resources, structural constraints, and patient access barriers including diversity and healthcare disparity challenges; recommendations to address challenges; and stakeholders to engage. This report details the deliberations and recommendations of a national symposium, " Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment," held in September 2010.

AB - Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor Program® (NMDP) will facilitate 10,000 transplants by 2015, double the current number. To better understand the existing personnel and center infrastructure for HCT in the country and to address system capacity challenges to the future growth of HCT, the NMDP convened a diverse group of stakeholders and thought leaders representing HCT physicians, physician assistants, nurse practitioners, nurses, pharmacists, other healthcare providers, HCT program directors, hospital administrators, payors, and professional organizations. Working groups were formed to identify: capacity issues because of shortages in human resources, structural constraints, and patient access barriers including diversity and healthcare disparity challenges; recommendations to address challenges; and stakeholders to engage. This report details the deliberations and recommendations of a national symposium, " Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment," held in September 2010.

KW - Hematopoietic cell transplantation

KW - National Marrow Donor Program

KW - System capacity

KW - Workforce shortage

UR - http://www.scopus.com/inward/record.url?scp=84855612460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855612460&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.10.004

DO - 10.1016/j.bbmt.2011.10.004

M3 - Article

C2 - 22178961

AN - SCOPUS:84855612460

VL - 18

SP - 172

EP - 182

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -